210 related articles for article (PubMed ID: 21935334)
1. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder.
Liu X; Chen Y; Faries DE
Clinicoecon Outcomes Res; 2011; 3():63-72. PubMed ID: 21935334
[TBL] [Abstract][Full Text] [Related]
2. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.
Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E
Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048
[TBL] [Abstract][Full Text] [Related]
3. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
6. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Ye W; Zhao Y; Robinson RL; Swindle RW
BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
9. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
10. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.
Monfared AA; Han D; Sheehy O; Bexton B; Lelorier J
Curr Med Res Opin; 2006 Jan; 22(1):83-94. PubMed ID: 16393434
[TBL] [Abstract][Full Text] [Related]
12. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
Liu X; Gelwicks S; Faries DE; Able SL
Int Clin Psychopharmacol; 2010 Nov; 25(6):315-22. PubMed ID: 20706125
[TBL] [Abstract][Full Text] [Related]
13. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
[TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on the pharmacoeconomics of escitalopram in depression.
Croom KF; Plosker GL
CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
18. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database.
Billioti de Gage S; Collin C; Le-Tri T; Pariente A; Bégaud B; Verdoux H; Dray-Spira R; Zureik M
CNS Drugs; 2018 Jul; 32(7):673-684. PubMed ID: 29959758
[TBL] [Abstract][Full Text] [Related]
19. Predictors of duloxetine adherence and persistence in patients with fibromyalgia.
Cui Z; Zhao Y; Novick D; Faries D
J Pain Res; 2012; 5():193-201. PubMed ID: 22792005
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
